diabetes

Showing 15 posts of 395 posts found.

astrazeneca_building_white

AstraZeneca’s Phase 3 Farxiga data impresses in type 2 diabetes

June 11, 2019
Manufacturing and Production, Research and Development AstraZeneca, diabetes, farxiga, pharma, type 2 diabetes

AstraZeneca has presented new Phase 3 data at the American Diabetes Association (ADA) 79th Scientific Sessions in San Francisco on …

Sanofi’s Soliqua proves superior to GLP-1 RA therapies in reducing blood sugar levels

June 10, 2019
Research and Development, Sales and Marketing Sanofi, Soliqua, diabetes, pharma, type 2 diabetes

Sanofi has stepped up at the American Diabetes Association (ADA) 79th Scientific Sessions in San Francisco, revealing new data which …

Novo’s oral semaglutide tops Jardiance and Victoza in two type 2 diabetes trials

June 10, 2019
Research and Development, Sales and Marketing Novo Nordisk, diabetes, pharma, semaglutide, type 2 diabetes

Novo Nordisk has taken the opportunity at the American Diabetes Association (ADA) 79th Scientific Sessions to pull back the curtain …

5204602349_c87b204860_z

Common diabetes drugs have been linked to a ‘flesh-eating’ genital infection

May 9, 2019
Medical Communications, Research and Development FG, diabetes, gangrene, health, necrotizing fasciitis

Patients taking some newer diabetes medications – SGLT2 inhibitors – have been warned that they may be at risk of …

smoking

Diabetes drug may help people quit smoking

May 1, 2019
Research and Development UTHealth, clinical trials, diabetes, smoking smoking cessation

A diabetes drug may help people quit smoking, according to researchers at the University of Texas Health Science Center at …

shutterstock_243110086

Sanofi and Lexicon’s Zynquista scores EU approval for type 1 diabetes patients

April 29, 2019
Sales and Marketing Lexicon, Sanofi, Type 1 diabetes, Zynquista, diabetes, pharma

The European Commission has authorised the use of Sanofi and Lexicon’s Zynquista (sotagliflozin) in Europe in the treatment of specific …

janssen_latest_logo_on_sign

Janssen’s Invokana combo smashes primary and secondary endpoints in chronic kidney disease

April 16, 2019
Manufacturing and Production, Research and Development Janssen, cardiovascular, chronic kidney disease, diabetes, invokana, pharma

Janssen has unveiled promising new Phase 3 for its sodium-glucose transport (SGLT) protein-2 inhibitor Invokana (canagliflozin), showing that the therapy …

novo_nordisk_flag

Novo Nordisk’s oral semaglutide outclasses Januvia with new data in type 2 diabetes

March 26, 2019
Manufacturing and Production, Research and Development Novo Nordisk, Ozempic, diabetes, pharma, type 2 diabetes

Novo Nordisk has revealed new dose-specific Phase 3a data for its glucagon-like peptide-1 (GLP-1) analogue oral semaglutide, indicating that the …

fda2outsideweb

Sanofi and Lexicon’s Zynquista denied type 1 diabetes approval by FDA complete response letter

March 25, 2019
Sales and Marketing Zynquista. FDA, diabetes, pharma

Sanofi and Lexicon’s Zynquista (sotagliflozin) has hit a hurdle on its way to US approval for the treatment of type …

astrazeneca_building_white

AZ’s diabetes drug Forxiga secures EU approval for adjunctive use in type 1 patients

March 25, 2019
Sales and Marketing AstraZeneca, Forxiga, diabetes, pharma

AstraZeneca has revealed that its sodium-glucose co-transporter 2 (SGLT2) inhibitor Forxiga (dapagliflozin) has secured approval from the European Commission for …

23andMe to offer genetic reports on diabetes

March 11, 2019
Sales and Marketing 23andME, Genentech, GlaxoSmithKline, Lundbeck, diabetes, genetics, genomics

Personal genomics company, 23andMe will offer customers information on the likelihood that they are genetically predisposed to developing type 2 …

4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

February 22, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Cancer, China, MedImmune, Xeljanz, asthma, diabetes, keytruda, osteoarthritis, pharma, rare disease

Happy Friday! With the weekend within reach, check out our run-down of the top ten most popular articles on Pharmafile.com …

5204602349_c87b204860_z

FDA to crack down on dietary supplements

February 12, 2019
Manufacturing and Production Alzheimer's, Alzheimers, Cancer, Dietary Supplements, FDA, USA, diabetes

The FDA is cracking down on those selling ‘dietary supplements’, having sent warning letters to companies who claim, without proof, …

novo_nordisk_flag

Novo Nordisk’s semaglutide meets primary endpoint of reducing cardiovascular events at Phase 3

November 26, 2018
Research and Development, Sales and Marketing Novo Nordisk, diabetes, pharma, semaglutide

Novo Nordisk has revealed new Phase 3a data for its investigational GLP-1 analogue therapy semaglutide, showing that the drug met …

The Gateway to Local Adoption Series

Latest content